Vemurafenib in melanoma with BRAF V600E mutation.

Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol (2013) 1.77

Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol (2012) 1.45

Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist (2013) 1.41

Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. J Clin Oncol (2015) 1.19

Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents. J Hematol Oncol (2014) 1.11

Mechanism and consequences of RAF kinase activation by small-molecule inhibitors. Br J Cancer (2014) 0.97

RASopathic skin eruptions during vemurafenib therapy. PLoS One (2013) 0.91

Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy. J Invest Dermatol (2013) 0.87

Appearance of New Vemurafenib-associated Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New Pigmented Lesions in Patients with Metastatic Malignant Melanoma After Initiating Treatment with Vemurafenib. J Clin Aesthet Dermatol (2013) 0.83

Genetics of melanocytic nevi. Pigment Cell Melanoma Res (2015) 0.81

Propranolol induced G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway. Oncotarget (2016) 0.78

Managing Side Effects of Vemurafenib Therapy for Advanced Melanoma. J Adv Pract Oncol (2015) 0.78

Human nevi lack distinguishing senescence traits. Aging (Albany NY) (2013) 0.78

Dormant melanomas or changing nevi? J Invest Dermatol (2014) 0.76

Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature. Dermatol Res Pract (2016) 0.75

Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68

Magnetic domain-wall racetrack memory. Science (2008) 8.24

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43

A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53

Chiral spin torque at magnetic domain walls. Nat Nanotechnol (2013) 2.98

Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol (2009) 2.94

Telemedical wound care using a new generation of mobile telephones: a feasibility study. Arch Dermatol (2005) 2.91

Dermoscopic examination of nail pigmentation. Arch Dermatol (2002) 2.83

Current-controlled magnetic domain-wall nanowire shift register. Science (2008) 2.68

International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev (2003) 2.25

Dependence of current and field driven depinning of domain walls on their structure and chirality in permalloy nanowires. Phys Rev Lett (2006) 2.11

Diagnosis and management of nail pigmentations. J Am Acad Dermatol (2007) 1.73

Time required for a complete skin examination with and without dermoscopy: a prospective, randomized multicenter study. Arch Dermatol (2008) 1.53

Dermoscopic evaluation of amelanotic and hypomelanotic melanoma. Arch Dermatol (2008) 1.51

Sarcoidosis and melanoma: a referral center study of 1,199 cases. Dermatology (2009) 1.49

Distinctive features of melanoma and its management in elderly patients: a population-based study in France. JAMA Dermatol (2013) 1.49

Variations in management of stage I to stage III cutaneous melanoma: a population-based study of clinical practices in France. Arch Dermatol (2008) 1.45

The CDK4-pRB-E2F1 pathway controls insulin secretion. Nat Cell Biol (2009) 1.45

The furrow ink test: a clue for the dermoscopic diagnosis of acral melanoma vs nevus. Arch Dermatol (2008) 1.44

Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab. Leuk Lymphoma (2013) 1.43

GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a beta-arrestin 1-mediated ERK1/2 activation in pancreatic beta-cells. J Biol Chem (2009) 1.36

mda-9/Syntenin: a positive regulator of melanoma metastasis. Cancer Res (2005) 1.35

Frequency of dermoscopic nevus subtypes by age and body site: a cross-sectional study. Arch Dermatol (2011) 1.34

Extranuclear estrogen receptor-alpha stimulates NeuroD1 binding to the insulin promoter and favors insulin synthesis. Proc Natl Acad Sci U S A (2010) 1.28

Dermoscopic Features of Onychomatricoma: A Study of 34 Cases. Dermatology (2015) 1.23

Extracellularly regulated kinases 1/2 (p44/42 mitogen-activated protein kinases) phosphorylate synapsin I and regulate insulin secretion in the MIN6 beta-cell line and islets of Langerhans. Endocrinology (2004) 1.20

Enhanced stochasticity of domain wall motion in magnetic racetracks due to dynamic pinning. Nat Commun (2010) 1.15

Accuracy in melanoma detection: a 10-year multicenter survey. J Am Acad Dermatol (2011) 1.15

Current driven domain wall velocities exceeding the spin angular momentum transfer rate in permalloy nanowires. Phys Rev Lett (2007) 1.15

Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma. J Med Genet (2011) 1.14

In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther (2007) 1.14

ERK1/2 control phosphorylation and protein level of cAMP-responsive element-binding protein: a key role in glucose-mediated pancreatic beta-cell survival. Diabetes (2006) 1.13

Characteristics of the coexistence of melanoma and renal cell carcinoma. Cancer (2010) 1.08

Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet (2013) 1.04

Subungual blue nevus. J Am Acad Dermatol (2003) 1.04

Degradation of cAMP-responsive element-binding protein by the ubiquitin-proteasome pathway contributes to glucotoxicity in beta-cells and human pancreatic islets. Diabetes (2009) 1.02

Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer (2012) 1.00

Dermoscopic evaluation of nodular melanoma. JAMA Dermatol (2013) 0.99

Clinical and sociodemographic characteristics associated with thick melanomas. A population-based, case-case study in France. Arch Dermatol (2012) 0.98

Surgical Pearl: Dermoscopy of the free edge of the nail to determine the level of nail plate pigmentation and the location of its probable origin in the proximal or distal nail matrix. J Am Acad Dermatol (2006) 0.92

Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients. Cancer (2014) 0.91

Targeted therapies in metastatic melanoma: toward a clinical breakthrough? Anticancer Agents Med Chem (2010) 0.90

β-Arrestin2 plays a key role in the modulation of the pancreatic beta cell mass in mice. Diabetologia (2013) 0.89

Dermoscopy provides useful information for the management of melanonychia striata. Dermatol Ther (2007) 0.89

Discrete domain wall positioning due to pinning in current driven motion along nanowires. Nano Lett (2010) 0.89

Combination of fluconazole and alpha-tocopherol in the treatment of yellow nail syndrome. J Drugs Dermatol (2009) 0.89

Benign dermoscopic parallel ridge pattern variants. Arch Dermatol (2011) 0.89

Elastosis perforans serpiginosa associated with pseudo-pseudoxanthoma elasticum during treatment of Wilson's disease with penicillamine. Dermatology (2005) 0.89

beta-Arrestin 1 is required for PAC1 receptor-mediated potentiation of long-lasting ERK1/2 activation by glucose in pancreatic beta-cells. J Biol Chem (2008) 0.88

New founder germline mutations of CDKN2A in melanoma-prone families and multiple primary melanoma development in a patient receiving levodopa treatment. Genes Chromosomes Cancer (2007) 0.88

Histological features and treatment approach of trichoblastic carcinomas: from a case report to a review of the literature. Tumori (2012) 0.88

Acrodermatitis continua of Hallopeau treated successfully with ustekinumab and acitretin after failure of tumour necrosis factor blockade and anakinra. Dermatology (2014) 0.88

Dermoscopy of Merkel cell carcinoma. Dermatology (2012) 0.88

Linear atrophoderma of moulin: report of 4 cases and 20th anniversary case review. Dermatology (2013) 0.87

Melanomas Associated With Blue Nevi or Mimicking Cellular Blue Nevi: Clinical, Pathologic, and Molecular Study of 11 Cases Displaying a High Frequency of GNA11 Mutations, BAP1 Expression Loss, and a Predilection for the Scalp. Am J Surg Pathol (2016) 0.86

Multiple adult xanthogranuloma: case report and literature review. Dermatology (2006) 0.86

Successful treatment of necrobiosis lipoidica with antimalarial agents. Arch Dermatol (2008) 0.85

Clinical and dermoscopic characteristics of desmoplastic melanomas. JAMA Dermatol (2013) 0.85

GLP-1-based strategies: a physiological analysis of differential mode of action. Physiology (Bethesda) (2014) 0.85

Using mathematical modeling in training planning. Int J Sports Physiol Perform (2006) 0.85

Prognostic factors of paraneoplastic pemphigus. Arch Dermatol (2012) 0.85

Dermoscopy of lymphomatoid papulosis. Arch Dermatol (2009) 0.85

The induction of apoptosis by local anesthetics: a comparison between lidocaine and ropivacaine. Anesth Analg (2003) 0.84

Skin cancers arising in tattoos: coincidental or not? Dermatology (2008) 0.83

Special locations dermoscopy: facial, acral, and nail. Dermatol Clin (2013) 0.83

Stevens-Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy. Radiother Oncol (2008) 0.83

Understanding and circumventing resistance to anticancer monoclonal antibodies. MAbs (2009) 0.83

Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas. Haematologica (2013) 0.83

Tracking of second primary melanomas in vemurafenib-treated patients. JAMA Dermatol (2013) 0.83

A clinico-dermoscopic approach for skin cancer screening: recommendations involving a survey of the International Dermoscopy Society. Dermatol Clin (2013) 0.83

Highly efficient in-line magnetic domain wall injector. Nano Lett (2015) 0.83

Structural requirements of the N-terminal region of GLP-1-[7-37]-NH2 for receptor interaction and cAMP production. Eur J Med Chem (2004) 0.82

Miniglucagon (MG)-generating endopeptidase, which processes glucagon into MG, is composed of N-arginine dibasic convertase and aminopeptidase B. Endocrinology (2004) 0.82

Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family. J Am Acad Dermatol (2012) 0.82

The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma. Br J Cancer (2008) 0.81

New therapeutical strategies in the treatment of metastatic disease. Dermatol Ther (2012) 0.81

Modelling training response in elite female gymnasts and optimal strategies of overload training and taper. J Sports Sci (2013) 0.80

Purification and structural characterization of de-N-acetylated form of GD3 ganglioside present in human melanoma tumors. Glycobiology (2007) 0.80

Ungueotropic T-cell lymphoma. Arch Dermatol (2006) 0.80

Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. J Clin Invest (2016) 0.80

A blue-gray subungual discoloration. Arch Dermatol (2007) 0.79